Clinical Trial Details
— Status: Terminated
Administrative data
NCT number |
NCT03670264 |
Other study ID # |
17-014620 |
Secondary ID |
UL1TR001878 |
Status |
Terminated |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
September 21, 2018 |
Est. completion date |
March 19, 2021 |
Study information
Verified date |
July 2021 |
Source |
Children's Hospital of Philadelphia |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
More than 90% of adult smokers initiate tobacco use before age 18, making prevention and
treatment of adolescent smoking a critical health priority. Behavioral economic interventions
utilizing financial incentives can promote smoking cessation in adult populations. No studies
have evaluated financial incentives among adolescents to promote engagement in effective
tobacco cessation programs through primary care settings. The goal of this study is to to
compare, through a pilot, randomized controlled trial, an intervention incentivizing contact
with a tobacco cessation program (the Quitline), an intervention incentivizing quitting, or
no financial incentive intervention on adolescent smoker enrollment and depth of engagement
in the tobacco cessation program.
Description:
Context:
Cigarette smoking remains a leading preventable cause of death in the United States (U.S.)
with substantial morbidity, mortality, and financial costs each year. More than 90% of adult
smokers initiate tobacco use before age 18, making prevention and treatment of adolescent
tobacco use a critical health priority. Further, e-cigarettes are now the most common tobacco
product used by teenagers, and adolescent use of e-cigarettes is strongly associated with
transition to cigarette use. Behavioral economic interventions utilizing financial incentives
can promote smoking cessation in adult populations. No studies have evaluated financial
incentives among adolescents to promote engagement in effective tobacco cessation programs
through primary care settings.
Objectives:
Primary Objective: To compare, through a pilot, randomized controlled trial, an intervention
incentivizing contact with the Quitline, an intervention incentivizing quitting, or no
financial incentive intervention on adolescent enrollment and depth of engagement in a
tobacco cessation program (Free Smoker Quitline).
Secondary Objective: To compare cotinine-confirmed 2-month quit rates across the 3 groups,
among users who report abstinence.
Study Design:
This is a randomized controlled trial of a Quitline incentive versus tobacco cessation
incentive versus no financial incentive on adolescent engagement with a tobacco cessation
program.
Setting/Participants:
Setting: Primary care sites within the Children's Hospital of Philadelphia (CHOP's) Pediatric
Research Consortium along with other non-clinical community settings.
60 adolescent tobacco users will be recruited. Eligibility criteria include adolescents (aged
14-21 years), who speak English, screen positive for tobacco use during their routine well
child or acute visit, are interested in quitting, and have a smart phone.
Study Interventions and Measures:
Adolescents will be randomized to 1 of 3 financial incentive groups: (1) Quitline Incentive:
the payment structure emphasizes engaging with the Quitline, with an additional smaller
payment for tobacco cessation; (2) Tobacco Cessation Incentive: the payment structure
emphasizes quitting regardless of engagement with the quitline (though the quitline will be
presented as a helpful tool); and (3) no financial incentive. The Quitline is funded by the
Pennsylvania Department of Health and staffed by trained cessation counselors available 24
hours a day, 7 days a week.
Outcomes Measures: Objective 1: The main outcome of interest is adolescent completion of the
tobacco cessation program, defined as the proportion of tobacco users identified in the
clinic that enroll, use, and complete the Quitline program compared across the 3 groups.
Objective 2: The secondary outcome is to confirm abstinence, via salivary cotinine
concentration of <30 ng per milliliter at 10 weeks after the start of the study.